Compare GDTC & IDAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GDTC | IDAI |
|---|---|---|
| Founded | 2018 | 2016 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.4M | 12.9M |
| IPO Year | 2021 | 2022 |
| Metric | GDTC | IDAI |
|---|---|---|
| Price | $0.97 | $2.46 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 5.2K | ★ 32.8K |
| Earning Date | 04-24-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 76.50 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $103.06 |
| Revenue Next Year | N/A | $140.06 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.73 | $1.80 |
| 52 Week High | $3.68 | $5.28 |
| Indicator | GDTC | IDAI |
|---|---|---|
| Relative Strength Index (RSI) | 44.84 | 47.11 |
| Support Level | $0.88 | $2.31 |
| Resistance Level | $1.06 | $2.80 |
| Average True Range (ATR) | 0.04 | 0.15 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 58.33 | 28.78 |
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
T Stamp Inc develops and markets identity authentication software solutions for enterprise partners and peer-to-peer markets. The company is engaged in developing proprietary artificial intelligence-powered solutions; researching and leveraging biometric science, cryptography, and data mining to deliver insightful identity & trust predictions while identifying and defending against fraudulent identity attacks, protecting sensitive user information, and extending the reach of digital services through accessibility. The artificial intelligence-powered solutions segment generates revenue principally from software licenses, professional services, and recurring Software-as-a-Service ("SaaS") revenue.